Easy patient management and monitoring – with Tumor Markers

When used in conjunction with other clinical procedures, our in-vitro diagnostics solutions aid in the management of breast cancer patients. CEA, CA 15-3 and BR 27.29 are useful tools for monitoring and detecting recurrences in previously treated Stage II or Stage III breast cancer patients. The Serum HER-2/neu test can be used in aftercare to monitor HER-2/neu levels in patients with metastatic breast cancer whose pre-treatment Serum HER-2/neu was greater than 15 ng/mL.

“My first experiences with measuring Serum HER-2/neu for metastatic breast cancer showed that in many cases, after patients were given chemotherapy, if the treatment was working, serum levels would rapidly decrease in the first three to four weeks after treatment. We confirmed our serum readings with a CT scan.”

Jean-Pierre Lotz, MD, Chief Medical Oncologist, Université Pierre et Marie Curie’s Hôpital Tenon, Paris, France

Serum tumor markers cannot be interpreted as absolute evidence of the presence or absence of malignant disease. Measurements should always be used in conjunction with other diagnostic procedures.